The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.
YuJung Kim
No relevant relationships to disclose
Jisu Oh
No relevant relationships to disclose
Tae Min Kim
No relevant relationships to disclose
Sae-Won Han
No relevant relationships to disclose
Keun Wook Lee
No relevant relationships to disclose
Jee Hyun Kim
No relevant relationships to disclose
Seock-Ah Im
No relevant relationships to disclose
Kyun-Seop Bae
Research Funding - Hanmi
Yook-Hwan Noh
No relevant relationships to disclose
Hyun-Jin Nam
Employment or Leadership Position - Hanmi
Kyung-Mi Park
Employment or Leadership Position - Hanmi
Jeewoong Son
Employment or Leadership Position - Hanmi
Yung-Jue Bang
Consultant or Advisory Role - Hanmi (U)
Research Funding - Hanmi